Stock exchanges & markets

Overview Watchlists

Basilea wins USD 30 million BARDA funding for phase 3 antifungal fosmanogepix

29. Jul 2026

(AWP Alliance News) - Basilea Pharmaceutica secured USD 30 million in additional BARDA funding to support its phase 3 program for the antifungal fosmanogepix. The award follows achievement of a prespecified enrollment milestone under the existing Other Transaction Agreement.

The new tranche lifts BARDA's committed funding since September 2024 to USD 123 million.

https://www.globenewswire.com/NewsRoom/ReleaseNg/402479808

Disclaimer: This news brief was created using generative artificial intelligence. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire on July 29, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • ETF Compass

    Stock exchanges & markets

    ETFs are becoming increasingly popular. Our ETF Compass helps you maintain an overview. Filter by criteria such as asset class, region, rating, return or costs. 

    Try the ETF Compass now

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now